Choosing the Right Tool for Genetic Engineering: Clinical Lessons from Chimeric Antigen Receptor-T Cells
The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
T cell modification with genes that encode chimeric antigen receptors (CAR-T cells) has shown tremendous promise for the treatment of B cell malignancies. The successful translation of CAR-T cell therapy to other tumor types, including solid tumors, is the next big challenge. As the field advances from second- to next-generation CAR-T cells comprising multiple genetic modifications, more sophisticated methods and tools to engineer T cells are being developed. Viral vectors, especially γ-retroviruses and lentiviruses, are traditionally used for CAR-T cell engineering due to their high transduction efficiency. However, limited genetic cargo, high costs of production under good manufacturing practice (GMP) conditions, and the high regulatory demands are obstacles for widespread clinical translation. To overcome these limitations, different nonviral approaches are being explored at a preclinical or clinical level, including transposon/transposase systems and mRNA electroporation and nonintegrating DNA nanovectors. Genome editing tools that allow efficient knockout of particular genes and/or site-directed integration of the CAR and/or other transgenes into the genome are also being evaluated for CAR-T cell engineering. In this review, we discuss the development of viral and nonviral vectors used to generate CAR-T cells, focusing on their advantages and limitations. We also discuss the lessons learned from clinical trials using the different genetic engineering tools, with special focus on safety and efficacy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Our findings demonstrate that IVT mRNA provides a transient, non-integrating platform, which mitigates theoretical safety concerns by avoiding risks of insertional mutagenesis and irreversible genomic alterations associated with viral vectors or CRISPR-Cas9 systems,11,12,13,14,18 while enabling sophisticated multiplexing strategies and potentially enhancing functional efficacy.28,29,30,31,32,45,65”
From Lipid nanoparticle mRNA delivery preserves CAR T cell cytotoxicity and limits exhaustion compared to electroporation (2026) · cites this paper as [12]
In the citing paper
“The absence of genomic integration and controlled expression kinetics align with regulatory priorities for safer cell engineering approaches, potentially easing clinical translation.12”
From Lipid nanoparticle mRNA delivery preserves CAR T cell cytotoxicity and limits exhaustion compared to electroporation (2026) · cites this paper as [12]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia
Maude, S. L., Laetsch, T. W., Buechner, J., Rives, S., Boyer, M., Bittencourt, H., Bader, P., Verneris, M. R., Stefanski, H. E., Myers, G. D., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709866 · Cited by 5,735
LMO2 -Associated Clonal T Cell Proliferation in Two Patients after Gene Therapy for SCID-X1
Hacein-Bey-Abina, S., Von Kalle, C., Schmidt, M., McCormack, M. P., Wulffraat, N., Leboulch, P., Lim, A., Osborne, C. S., Pawliuk, R., Morillon, E., et al. (2003) · Science · doi:10.1126/science.1088547 · Cited by 3,587
Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection
Eyquem, J., Mansilla-Soto, J., Giavridis, T., van der Stegen, S. J. C., Hamieh, M., Cunanan, K. M., Odak, A., Gönen, M., & Sadelain, M. (2017) · Nature · doi:10.1038/nature21405 · Cited by 1,831 · cited 1×
“Using this approach, targeted integration of CAR transgene into the TRAC gene locus led to enhanced T cell activity by promoting optimal CAR expression and alleviating T cell exhaustion following repeated exposure to antigen.(80) Disruption of TRAC postCAR integration can further generate allogeneic universal CAR-T ce…”
MethodFraietta, J. A., Lacey, S. F., Orlando, E. J., Pruteanu-Malinici, I., Gohil, M., Lundh, S., Boesteanu, A. C., Wang, Y., O’Connor, R. S., Hwang, W.-T., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0010-1 · Cited by 1,785
CRISPR-engineered T cells in patients with refractory cancer
Stadtmauer, E. A., Fraietta, J. A., Davis, M. M., Cohen, A. D., Weber, K. L., Lancaster, E., Mangan, P. A., Kulikovskaya, I., Gupta, M., Chen, F., et al. (2020) · Science · doi:10.1126/science.aba7365 · Cited by 1,478 · cited 2×
“Stadtmauer et al.(77) treated patients with refractory cancer with T cells in which CRISPR/Cas9 was used to disrupt 3 genes, TRAC, TRBC, and PDCD1, and a viral vector was used to introduce a tumor-directed TCR (NCT03399448).”
MethodMilone, M. C., Fish, J. D., Carpenito, C., Carroll, R. G., Binder, G. K., Teachey, D., Samanta, M., Lakhal, M., Gloss, B., Danet-Desnoyers, G., et al. (2009) · Molecular Therapy · doi:10.1038/mt.2009.83 · Cited by 1,197 · cited 1×
“The elongation factor 1-a (EF1-a) promoter drives higher levels of transgene expression over time in T cells and is therefore the promoter of choice for most CAR-T cell products.(17)”
BackgroundMultiplex genome editing to generate universal CAR T cells resistant to PD1 inhibition
Ren, J., Liu, X., Fang, C., Jiang, S., June, C. H., & Zhao, Y. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1300 · Cited by 942
Clinical use of lentiviral vectors
Milone, M. C., & O’Doherty, U. (2018) · Leukemia · doi:10.1038/s41375-018-0106-0 · Cited by 930
Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells
Qasim, W., Zhan, H., Samarasinghe, S., Adams, S., Amrolia, P., Stafford, S., Butler, K., Rivat, C., Wright, G., Somana, K., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aaj2013 · Cited by 902 · cited 2×
“Treatment of two infants with B-ALL with this universal CART cells showed successful induction of molecular remission and T cell persistence without significant GVHD.(66)”
BackgroundDisruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells
Fraietta, J. A., Nobles, C. L., Sammons, M. A., Lundh, S., Carty, S. A., Reich, T. J., Cogdill, A. P., Morrissette, J. J. D., DeNizio, J. E., Reddy, S., et al. (2018) · Nature · doi:10.1038/s41586-018-0178-z · Cited by 862 · cited 1×
“Characterization of this T lymphocyte population indicated that the CAR transgene had integrated into the TET2 locus in a patient with a hypomorphic mutation in the second TET2 allele.(28) A second study identified several integration sites in the TET2 locus, but no signs of clonal expansion were observed, indicating…”
Background
Research works printed but not linked: 67
- 10.1146/annurev-immunol-042718-041407 · DOI · Paper page
- 10.1056/NEJMra1706169 · DOI · Paper page
- 10.1016/j.copbio.2020.01.009 · DOI
- 10.1038/s41573-021-00155-y · DOI · Paper page
- 10.1038/s41573-021-00155-y · DOI · Paper page
- 10.1016/j.omtm.2018.12.009 · DOI · Paper page
- 10.3390/biomedicines4020009 · DOI
- 10.1126/sciadv.abf1333 · DOI · Paper page
- 10.2174/1566523054546224 · DOI · Paper page
- 10.1097/CJI.0b013e3182187600 · DOI · Paper page
- 10.1128/JVI.73.4.2886-2892.1999 · DOI · Paper page
- 10.1056/NEJM199008303230904 · DOI · Paper page
- 10.1126/scitranslmed.3003761 · DOI · Paper page
- 10.1016/j.ymthe.2017.10.012 · DOI · Paper page
- 10.1089/hum.2005.16.457 · DOI · Paper page
- 10.1182/blood-2017-02-769208 · DOI · Paper page
- 10.1089/hum.2012.203 · DOI · Paper page
- 10.1182/blood-2007-12-128751 · DOI · Paper page
- 10.1038/s43018-021-00207-7 · DOI
- 10.1172/JCI130144 · DOI · Paper page
- 10.1073/pnas.1919259117 · DOI · Paper page
- 10.1038/nmeth.1332 · DOI · Paper page
- 10.1002/bies.202000136 · DOI
- 10.1073/pnas.36.6.344 · DOI · Paper page
- 10.1016/S0092-8674(00)80436-5 · DOI · Paper page
- 10.1038/mt.2016.11 · DOI · Paper page
- 10.1172/JCI86721 · DOI · Paper page
- 10.1158/0008-5472.CAN-07-5600 · DOI · Paper page
- 10.1016/j.surg.2019.05.047 · DOI
- 10.18632/oncotarget.9955 · DOI
- 10.1016/j.ymthe.2020.05.021 · DOI
- 10.1172/JCI138473 · DOI · Paper page
- 10.1038/mt.2016.51 · DOI
- 10.1089/hum.2017.136 · DOI
- 10.1016/j.jcyt.2019.03.562 · DOI
- 10.1182/blood-2018-99-111419 · DOI · Paper page
- 10.1182/blood-2019-129562 · DOI
- 10.1089/hum.2008.068 · DOI · Paper page
- 10.1158/0008-5472.CAN-10-2880 · DOI · Paper page
- 10.18632/oncotarget.5029 · DOI · Paper page
- 10.1158/2326-6066.CIR-13-0170 · DOI · Paper page
- 10.1080/2162402X.2020.1792625 · DOI
- 10.1111/exd.13678 · DOI
- 10.3109/10428194.2011.634048 · DOI · Paper page
- 10.1038/mt.2016.146 · DOI · Paper page
- Cummins KD, , Frey N, , Nelson AM, et al. Treating relapsed/refractory (RR) AML with biodegradable anti-CD123 CAR modified T cells. Blood, 2017; 130:1359.
- 10.1182/blood-2018-03-837609 · DOI · Paper page
- 10.1158/2326-6066.CIR-13-0006 · DOI · Paper page
- 10.1053/j.gastro.2018.03.029 · DOI · Paper page
- 10.1158/2326-6066.CIR-17-0189 · DOI · Paper page
- 10.1093/nar/gky289 · DOI
- 10.1146/annurev-genet-110410-132435 · DOI · Paper page
- 10.1038/s41580-019-0131-5 · DOI · Paper page
- 10.1126/science.1231143 · DOI · Paper page
- 10.1126/science.1232033 · DOI · Paper page
- 10.1126/science.1225829 · DOI · Paper page
- 10.1038/cr.2016.142 · DOI · Paper page
- 10.1182/blood-2017-01-761320 · DOI · Paper page
- 10.1080/2162402X.2017.1407898 · DOI
- 10.1158/1538-7445.AM2020-CT052 · doi:10.1158/1538-7445.am2020-ct052
- 10.1038/s41591-020-0840-5 · DOI · Paper page
- 10.1038/s41423-021-00749-x · DOI · Paper page
- 10.1016/j.ymthe.2017.02.005 · DOI · Paper page
- 10.15252/emmm.201809158 · DOI · Paper page
- 10.1038/s41408-021-00508-1 · DOI · Paper page
- 10.1016/S0140-6736(20)32334-5 · DOI · Paper page
- 10.1158/1078-0432.CCR-20-3863 · DOI · Paper page
Cited by
Picht, S., Farrera-Sal, M., Hiller, A. L., Brumhard, S., Klaas, A. M., Schulenberg, S., Friedrich, R., Scholz, C., Hemmerling, L., Simon, D. N., et al. (2026) · Molecular Therapy Nucleic Acids · doi:10.1016/j.omtn.2026.102929 · Cited by 7
Gene-sized DNA insertion at genomic safe harbors in human cells using a site-directed transposase
(2025) · doi:10.1093/nar/gkaf1316 · Cited by 2
Metadata
- Authors
- Irving, M., Lanitis, E., Migliorini, D., Ivics, Z., & Guedan, S.
- Affiliations
- Department of Oncology, Ludwig Institute for Cancer Research Lausanne, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
- Department of Oncology, Geneva University Hospitals, Geneva, Switzerland.
- Transposition and Genome Engineering, Division of Medical Biotechnology, Paul Ehrlich Institute, Langen, Germany.
- Department of Hematology and Oncology, Hospital Clinic, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.
- ORCID
- Guedan, Sonia
- Venue
- Human Gene Therapy
- Publisher
- SAGE Publications
- Published
- 2021-10
- Volume
- 32
- Issue
- 19-20
- Pages
- 1044-1058
- ISSN
- 1043-0342
- 1557-7422
- Cited by
- 113
- References
- 21
- Language
- en
- Licence
- creativecommons.org/licenses/by/4.0/ (vor)
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.